ACE Inhibitors in the Therapy of Ventricular Dysfunction after Cardiotoxic Cytostatics
Authors:
B. Mladosievičová
Authors‘ workplace:
Oddelenie klinickej patofyziológie Ústavu patologickej fyziológie Lekárskej fakulty Univerzity Komenského, Bratislava
Published in:
Čes. slov. Farm., 2004; , 55-60
Category:
Overview
Morbidity and mortality resulting from cardiotoxic complications of anticancer therapy is stillunacceptably high. Despite advances in the understanding of the pathomechanisms of cardiotoxicity,in prevention and detection of these complications, progressive ventricular dysfunction in cancersurvivors represents a great therapeutic problem. Ventricular dysfunction is a life-threateningcomplication particularly in patients treated with anthracycline cytostatics. Anthracycline-inducedloss of myocytes leads to an inadequate ventricular hypertrophy, which produces a rise in leftventricular (LV) afterload and deterioration of ventricular contractility culminating in heart failure.Efficacy of angiotensin-converting enzyme (ACE) inhibitors for the treatment of asymptomatic andsymptomatic LV dysfunction in various clinical settings has been confirmed in a number ofcontrolled, randomized trials. Until now, there are only few published data supporting the use ofACE inhibitors to treat patients with ventricular dysfunction-induced by anthracyclines. Cardioprotectionwith ACE inhibitors in children and adolescents treated with anthracyclines in contrastto ACE inhibition in adults after anthracycline therapy is a controversial topic. Evidence from therecent follow up study indicates a progressive deterioration of left ventricular wall thinning inchildhood cancer survivors treated with enalapril. The ongoing large controlled, double blind,randomized trials will provide an important information concerning the efficacy of ACE inhibitorsto prevent progression of ventricular dysfunction in paediatric oncologic patients.
Key words:
anthracyclines – late cardiotoxicity – ventricular dysfunction – heart failure –ACE inhibitors
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2004 Issue 2
Most read in this issue
- Catalytic Activity of Butyrylcholinesterase in Biodegradation of Organic AmmoniumSalts in vitro
- Slovak Nomenclature of Organic Chemistry
- Biological Availability of Ophthalmic Preparations. I. Increased Penetrability of theActive Ingredient Through the Cornea
- The in vitro Reactivation of O-Isopropylmethylfluorophosphonate – Inhibited Acetylcholinesteraseby Bisquaternary Oxime HS-6